BioMarin Pharmaceutical Inc. (FRA:BM8)
45.98
-0.37 (-0.80%)
At close: Dec 5, 2025
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $776.13M USD in the quarter ending September 30, 2025, with 4.08% growth. This brings the company's revenue in the last twelve months to $3.09B, up 12.39% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$3.09B
Revenue Growth
+12.39%
P/S Ratio
3.34
Revenue / Employee
$1.02M
Employees
3,040
Market Cap
8.82B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
| Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
BioMarin Pharmaceutical News
- 2 days ago - BMRN Experiences Downgrade and Price Target Cut by Leerink Partners | BMRN Stock News - GuruFocus
- 17 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 24 days ago - BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England - PRNewsWire
- 25 days ago - BMRN February 2026 Options Begin Trading - Nasdaq
- 4 weeks ago - BioMarin Pharmaceutical (BMRN) Downgraded by Stifel: Target Price Lowered | BMRN Stock News - GuruFocus
- 5 weeks ago - BioMarin (BMRN) Achieves FDA Priority Review for Expanded Use of Palynziq - GuruFocus
- 5 weeks ago - FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria - PRNewsWire
- 5 weeks ago - Beyond the Balance Sheet: What SWOT Reveals About BioMarin Pharmaceutical Inc (BMRN) - GuruFocus